Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios-Reference-Cited by-同舟云学术

Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios

Published:2013-10 Issue:10pt2 Volume:53 Page:2399-2412
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Bruhn Roberta¹²,Lelie Nico¹²,Custer Brian¹²,Busch Michael¹²,Kleinman Steven¹²,

Affiliation:

1. Blood Systems Research Institute; Lelie Research; San Francisco California Paris France

2. University of British Columbia; Canada

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.12299/fullpdf

Reference25 articles.

1. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009;Roth;Vox Sang,2012

2. Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms;Weusten;Transfusion,2011

3. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa;Vermeulen;Transfusion,2009

4. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy;Deeks;Immunity,2007

5. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT;Weusten;Transfusion,2002

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of pre-donation viral markers screening of new blood donors on blood safety;Transfusion Clinique et Biologique;2023-11

2. Evolution of Blood Safety in Switzerland over the Last 25 Years for HIV, HCV, HBV and Treponema pallidum;Viruses;2022-11-23

3. Efficacy of Different Testing Scenarios in Reducing Transfusion-Transmitted Hepatitis B Virus (TT-HBV) Infection Risk;Viruses;2022-10-15

4. Processing And Keeping Blood (Components) Products In Storage;J PHARM NEGAT RESULT;2022

5. Residual risk of transfusion‐transmitted hepatitis B virus ( TT‐HBV ) infection by NAT ‐screened blood components: A review of observed versus modeled infectivity from donors with window period and occult HBV infections;Transfusion;2021-09-29